Feature | February 26, 2013

Transcatheter Pulmonary Valve to Undergo Feasibility Study

FDA approves investigational device exemption to begin early feasibility studies for new develop new minimally invasive treatment

February 26, 2013 — Medtronic Inc. announced it received U.S. Food and Drug Administration (FDA) approval to conduct an early feasibility study using its self-expanding Native Outflow Tract Transcatheter Pulmonary Valve (TPV). This approval represents the first-ever FDA approval of an investigational device exemption (IDE) following the new draft FDA guidance for early feasibility studies.

“The approval of this study is an excellent example of how the FDA and manufacturers can work together to advance medical innovation by studying initial device design and functionality, with the long-term goal of delivering novel therapies to patients in need,” said John Liddicoat, M.D., senior vice president of Medtronic and president of the Medtronic structural heart business. “In this case, the early feasibility study will help us develop a minimally invasive therapy for patients whose only current treatment option is open-heart surgery.”

The Native Outflow Tract TPV is a minimally invasive therapy for patients with congenital heart disease who don’t have a right ventricle-to-pulmonary artery conduit, and need a pulmonary valve to maintain adequate blood flow from the right ventricle and the pulmonary artery. Delivered in a minimally invasive procedure using a catheter funneled through the veins, the valve is designed to restore pulmonary valve competency without invasive open-heart surgery.

The intent of the FDA’s draft guidance for investigational device exemptions for early feasibility medical device clinical studies, including first in human (FIH) studies, is to foster early-stage development of medical devices within the United States. It is a new approach to clinical studies conducted in the early stages of development, and is designed to facilitate early clinical experience with investigational medical devices to reach patients sooner and create incentives to innovate in the United States.

This new approach is intended to allow studies to start earlier in the device development process than previously allowed, while still providing appropriate human subject protections. It also permits manufacturers and FDA device reviewers more flexibility to make device modifications once the study begins.

The Medtronic early feasibility study will evaluate the design, procedural success and initial performance of the Native Outflow Tract TPV to enable further development of the device prior to conducting an additional clinical study.

Medtronic already has several years experience with transcatheter pulmonary valves with its Melody valve. It was cleared for limited use by the FDA under a humanitarian device exemption for use in fewer than 1,000 patients a year. It has been primarily used in pediatric patients.

For more information: www.medtronic.com

 

Related Content

transcatheter repair of a mitral valve paravalvular leak

Transcatheter repair of a surgical mitral replacement paravalvular leak with an Amplatzer Vascular Plug II.

Feature | Heart Valve Repair| February 08, 2016 | Dave Fornell
Off-label use of the St.
News | Cardiac Diagnostics| February 08, 2016
February 8, 2016 — A parent’s incarceration has immediate, devastating effects on a family.
medical imaging, low-dose radiation, cancer, LNT model study
News | Radiation Dose Management| February 04, 2016
The widespread belief that radiation from X rays, CT scans and other medical imaging can cause cancer is based on an...
caffeine consumption, extra heartbeats, UCSF study, UC San Francisco, Journal of the American Heart Association
News | EP Lab| February 04, 2016
Contrary to current clinical belief, regular caffeine consumption does not lead to extra heartbeats, which, while...
sleep apnea, heart failure readmissions, Thomas Jefferson University study
News | Heart Failure| February 04, 2016
Early diagnosis and treatment of sleep apnea may reduce six-month readmissions for patients hospitalized with heart...
News | Heart Failure| February 04, 2016
New research from scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) published in the journal...
medtronic corevalve, tavr
News | February 03, 2016 | Dave Fornell
Medtronic announced Feb. 3 that the U.S.
Allegheny General Hospital, MRI, patients with implantable cardiac devices, safety and effectiveness
News | EP Lab| February 01, 2016
The findings of a major study led by cardiovascular imaging specialists at Allegheny General Hospital (AGH) suggest...
News | EP Lab| January 29, 2016
Diseased hearts may be thrown out of rhythm by structural differences, now visible for the first time, in protein...
TOBA-BTK study, six-month results, LINC 2016, Tack Endovascular System
News | Peripheral Arterial Disease (PAD)| January 29, 2016
Intact Vascular Inc. announced that positive six-month results from its Tack Optimized Balloon Angioplasty – Below-the-...
Overlay Init